Whither the Hippocampus? FDG-PET Hippocampal Hypometabolism in Alzheimer Disease Revisited

BACKGROUND AND PURPOSE: The hippocampus is a widely recognized area of early change in AD, with volume loss consistently reported across a wide variety of MR imaging studies, sample sizes, methodologies, and instruments.\(^1\) The case for altered hippocampal metabolism in AD, and, more specifically, for whole-brain FDG-PET, has been less clear and even divergent between studies. Most metabolic neuroimaging studies have failed to show hippocampal dysfunction in AD and MCI.\(^2,3\) A consistent and striking finding has been the lack of hippocampal metabolic differences on whole-brain FDG-PET using statistical parametric mapping–based (SPM; Wellcome Depart-

T

Published June 14, 2012 as 10.3174/ajnr.A3113

mament of Imaging Neuroscience, London, UK) voxelwise analysis methods comparing patients with AD and CN control subjects.\(^2,^-6\) Group comparisons using these voxelwise PET methods have consistently shown hypometabolism in the cingulate gyrus and temporoparietal areas for AD but, interest-

ingly, not in the hippocampus. Some ROI-based methods, however, have shown hypometabolism in the hippocampus for AD,\(^3,^-7,^-10\) and a variety of studies have attempted to ad-

dress this apparent inconsistency between voxelwise and ROI-

based methods. Many of these investigations have centered on potential methodologic artifacts or discrepancies related to spatial resolution, partial volume effects, inaccuracies in PET-MRI coregistration, and the method of PET intensity normalization.\(^2,^-4,^-11,^-12\) The lack of hippocampal metabolic change (and, more specifically, hypometabolism in AD) associated with SPM-style voxelwise analyses, however, has not been ade-

quately explained. We hypothesize that the source of the ap-

parent discrepancy can be traced to the analytic methods and the nature of the question being posed in the analysis.

Voxelwise methods applied to FDG-PET data typically adapt techniques from VBM developed for MR imaging structural analysis.\(^13^-17\) For PET data, this involves 1) coregistration of the native subject PET data to the native MR imaging, 2) spatial normalization of the subject MRI scan to an atlas or study template (usually based on gray matter segmented tissue maps), and 3) application of the transformation parameters from the MR imaging normalization to the coregistered PET

Received January 31, 2012; accepted after revision February 20, 2012.
From the Department of Radiology (J.A.M., C.T.W.) and Translational Science Institute (C.T.W.), Wake Forest School of Medicine, Winston-Salem, North Carolina.
* Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) data base [http://adni.loni.ucla.edu]. As such, the investi-
gators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at http://adni.loni.ucla.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf

Please address correspondence to Joseph Maldjian, MD, Department of Radiology, Wake Forest University Health Sciences, Winston-Salem, NC 27157; e-mail: maldjian@wakehealth.edu

Indicates open access to non-subscribers at www.ajnr.org

Indicates article with supplemental on-line table.

EBM2 indicates Evidence-Based Medicine Level 2 as designated by peer reviewers.

http://dx.doi.org/10.3174/ajnr.A3113

AJNR Am J Neuroradiol  ●  2012  |  www.ajnr.org

Copyright 2012 by American Society of Neuroradiology.
data. These steps bring the individual subject PET images into alignment with each other in template space, allowing voxelwise analysis of differences using standard SPM-style 2-sample $t$-statistics. In comparison with the MRI-based VBM pipeline, there is a critical step that is universally omitted. In MRI-based analysis, the spatially normalized images are modulated, with the determinant of the Jacobian specifying the degree of expansion or contraction at each voxel. This is necessary to preserve gray matter volumes, as a perfect normalization would show no differences in the spatially normalized images alone (referred to as gray matter concentration). Specifically, a voxel that is segmented as 100% gray matter (concentration) on MR imaging will not vary in gray matter content between populations, and hence, a perfect MR imaging spatial normalization will show no differences in gray matter concentration between template and normalized subject. With the advent of highly accurate high-dimensional normalization algorithms, this realization has led to a method of analysis termed tensor-based morphometry, in which group differences are identified entirely on the basis of the shape change parameters rather than the spatially normalized images that, alone, would carry very little information on the structural differences. The situation for PET is different, in that voxels can show differential FDG activity despite having equal gray matter content. In addition, the assumption that coregistration between PET and MR imaging can be performed accurately in diseased states, for the purposes of applying MR imaging normalization parameters, can be called into question. For example, diseased hippocampal activity on PET imaging may not be reflective of the entire spatial extent of the hippocampus visible to the human observer or to a computer algorithm on the corresponding MRI, which is a central assumption for accurate coregistration between structures.

In this study, we investigate hippocampal metabolic activity in AD using a PET-specific framework with a novel high-dimensional normalization strategy, while accounting for the degree of spatial deformation. Previous MRI-related normalization methodologic confounds are addressed by using a PET-specific population template. The purpose of this study is to determine whether important hippocampal metabolic FDG-PET activity differences in whole-brain voxelwise analyses between patients with AD and normal controls are embedded in the Jacobian information generated during spatial normalization.

**Materials and Methods**

Data used in the preparation of this article were obtained from the ADNI database (adni.loni.ucla.edu). The ADNI was launched in 2003 by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, the Food and Drug Administration, private pharmaceutical companies and non-profit organizations, as a $60 million, 5-year public-private partnership. The primary goal of ADNI has been to test whether serial MR imaging, positron emission tomography, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of MCI and early AD. Determination of sensitive and specific markers of very early AD progression is intended to aid researchers and clinicians to develop new treatments and monitor their effectiveness, as well as lessen the time and cost of clinical trials.

The Principal Investigator of this initiative is Michael W. Weiner, MD, VA Medical Center and University of California–San Francisco. ADNI is the result of efforts of many co-investigators from a broad range of academic institutions and private corporations, and subjects have been recruited from over 50 sites across the U.S. and Canada. The initial goal of ADNI was to recruit 800 adults, ages 55 to 90, to participate in the research, approximately 200 cognitively normal older individuals to be followed for 3 years, 400 people with MCI to be followed for 3 years and 200 people with early AD to be followed for 2 years. For up-to-date information, see www.adni-info.org.

**Participants**

We used available baseline PET-FDG data, as described in the ADNI acquisition protocol, from 102 CN subjects (average age 75.8 years; 62 male, 40 female) and 92 patients with AD (average age 75.5 years, 55 male, 37 female) participants. Subject IDs are provided in the On-Line Table.

**PET Scans**

Preprocessing by ADNI project investigators includes reorientation to a common spatial orientation, resampling to 1.5-mm isotropic dimension, and intensity normalization to a subject-specific mask, such that voxel values in the mask sum to 1. The intensity normalization step was designed to account for differences introduced by the use of multiple scanners.

**Standard PET Processing Framework**

Before describing our image processing methodology, we first briefly review the standard PET processing framework, followed by a conceptualized description of spatially normalized, modulated, and Jacobian maps. In the typical PET processing pipeline, spatial normalization alone is performed based on MR imaging parameters, without any modulation with the Jacobian. After spatial normalization, the activity in the native image is resampled to the space of the template image. The voxel values are not altered. Comparison of these images asks the question, “Does average FDG activity differ between structures?” This does not take into account the effects of atrophy or changes in local spatial distribution of activity (eg, up- or down-regulation). Figure 1 demonstrates a conceptualized normalization for a representative atrophied area. After spatial normalization to a template of 16 voxels for the hippocampus, if the activity in an atrophied hippocampus (eg, 1 count for each of 4 voxels; Fig 1B) is the same as that for a normal hippocampus (1 count for each of 16 voxels in Fig 1A), there will be no difference between the normal and diseased areas (1 count for each of 16 voxels; Fig 1D). Modulation of the spatially normalized images with the amount of shape change (Jacobian) scales the voxel values to reflect the original volume of the structure. A comparison of modulated images asks the question, “Does total activity differ between structures?” Using the same example, the 1 count in each of 16 voxels is now scaled for the degree of expansion, reducing the value to 0.25 in each of the 16 voxels for the diseased case (Fig 1E). The Jacobian maps derived from the spatial normalization parameters quantify the degree of local expansion or contraction required to match the template. If there is no difference in average activity, all the differences will be present in the Jacobian deformation fields.

**Symmetric Diffeomorphic Registration**

Identification of brain imaging differences in populations is highly dependent on precise alignment between different subjects. SyN uses diffeomorphisms (differentiable and invertible maps with a differen-
iability (and the expensive inverse) to capture both large deformations and small shape changes. In the largest evaluation of nonlinear brain registration algorithms to date, SyN provided the most consistently high accuracy across subjects and label sets.

Custom Template Construction
A PET custom study-specific template was built using a diffeomorphic shape and intensity averaging technique. The PET template was constructed from 397 ADNI participants (102 CN, 203 with MCI, and 92 with AD, including participants for this study). Parameters for the template construction procedure included a 4-level Gaussian pyramid as the multiresolution strategy and the cross-correlation similarity metric, with 200 maximum iterations. This yielded an unbiased average shape and appearance template, as well as the set of diffeomorphisms and inverse diffeomorphisms that map from the template to each individual. The resulting PET study template was then normalized, using SyN to the Montreal Neurological Institute space PET template provided in SPM resampled to 1-mm isotropic voxel dimensions.

PET Spatial Normalization
The subject-specific inverse deformation parameters computed from the PET population template generation procedure were combined with the custom PET template to Montreal Neurological Institute space normalization parameters to bring the PET individual subject images into Montreal Neurological Institute space in a single resampling step.

Modulation and Tensor-Based Morphometry
The nonlinear transformations from the SyN procedure provide deformation tensor fields describing the voxelwise shape changes from the template to each subject’s brain. The Jacobian determinants of these deformation fields indicate the fractional volume expansion and contraction at each voxel required to match the template. PET-specific modulated maps were generated by multiplying the spatially normalized PET images by the respective Jacobian determinants.

Statistical Group Comparisons
Voxelwise analyses were performed to identify regional variation in FDG activity between patients with AD and CN subjects using the 2-sample t test model in SPM8. Group comparisons were performed for 1) spatially normalized raw PET, 2) modulated PET (spatially normalized × Jacobian), and 3) Jacobian PET (tensor-based morphometry). For the spatially normalized raw PET data modeling in SPM, no additional intensity scaling (eg, proportional scaling) was performed, as the preprocessed PET data downloaded from the ADNI data base were already subject to intensity scaling. In addition to whole-brain comparisons, an hpa ROI mask was constructed using the automated anatomical labeling atlas as implemented by the wfu_pickatlas for ROI-based hypothesis testing in SPM8. All statistical parametric maps were thresholded at $P < .05$ and corrected for multiple comparisons using a stringent FWE-rate Bonferroni correction for the whole-brain maps or the false discovery rate for the hippocampal masked data.

Standard PET Processing
For comparison purposes, we also performed analysis of the data using a standard PET processing pipeline. PET images from each subject were coregistered to their corresponding MRI T1-weighted image using the mutual information algorithm in SPM8. The individual subject MR images were segmented and normalized to Montreal Neurological Institute space using the Dartel high-dimensional warping and the SPM8 new segment procedure, as implemented in the VBM8 toolbox. The coregistered PET images were normalized to Montreal Neurological Institute space using the transforms computed for the corresponding structural MR imaging. Effect sizes (Cohen’s d; correlation coefficient, r) were computed between the AD and CN groups using the hpa ROI for the following 3 analysis methods: modulated PET (custom PET template), standard PET-MRI, and MR imaging only (modulated gray matter VBM MRI images from the SPM8 new segment procedure). In addition, sample-size plots were generated for each analysis method using the hpa ROI with a type I error rate of .05.

Results
Spatially Normalized Raw PET Data
SPMt maps for CN-AD, using a stringent $P < .05$ FWE multiple comparisons correction, demonstrated metabolic differences in the posterior cingulate and bilateral parietal areas (Fig 2). There were no hippocampal regions that survived correction on the whole-brain analysis. With the use of the hippocampal ROI mask, however, bilateral hippocampal metabolic differences were apparent (Fig 3).

Modulated PET Data (Custom Template)
The modulated PET whole-brain SPMt analysis for CN-AD ($P < .05$, FWE corrected) demonstrated strong bilateral
hippocampal metabolic differences as well as differences in the posterior cingulate (Fig 4). The parietal differences were no longer apparent. With the hpa mask, CN-AD demonstrated even more robust differences in the hippocampus (Fig 5).

**Jacobian PET Data**

Whole-brain comparison of CN-AD on the Jacobian maps (P < .05, FWE corrected) demonstrated exclusively bilateral hippocampal metabolic differences (Fig 6). Other areas, including the cingulate and parietal regions, no longer survived multiple comparison correction. With the use of the hpa mask, strong hippocampal differences were again identified on the CN-AD (Fig 7).

**Effect Sizes**

Effect sizes for the modulated PET data (custom PET template) were 1.12 and 0.49 (Cohen d and r, respectively). Effect sizes for the standard PET-MRI analysis were 0.47 and 0.23, while, for structural MR imaging alone, effect sizes were 1.58 and 0.62. Sample sizes for detecting a difference at 80% power with a .05 Type I error rate were 8, 12, and 68 subjects per group, for MR imaging alone, modulated PET, and standard PET, respectively (Fig 8).

**Discussion**

Whole-brain voxelwise analyses of FDG-PET data in studies of AD have been notoriously devoid of differences in the hippocampus. This has been ascribed to a variety of factors, including partial volume effects, limited spatial resolution, and poor registration between PET and MR imaging, but a definitive explanation has been lacking. We demonstrate that the hippocampal differences are not just present in the FDG-PET data—they are massive in scope and are comparable with those identified for structural MR imaging.

**Hippocampal Activity Differences Embedded in Jacobian Determinants**

The negative findings in previous FDG-PET reports stem from a processing approach adapted from the MRI VBM literature and the nature of the underlying comparisons in the activity being performed. Specifically, much of the activity difference is contained in the Jacobian information from the spatial normalization procedure. While the Jacobian is used for MRI VBM processing (modulated data, or tensor-based morphometry), it has instead been discarded in the PET processing pipeline. Because the warp fields are typically computed between individual subject MR imaging and template MR imaging, and subsequently applied to coregistered PET data, it does not make sense to use this Jacobian information, as it...
would provide only a measure of MR imaging differences. We have taken the approach of generating a PET-study-specific template for the normalization procedure, rather than relying on coregistration between PET and MR imaging. Thus, the Jacobian information reflects only PET-related differences in populations, with no relationship to the MR imaging normalization procedure. Using this approach, large differences are identified specifically in the hippocampus on both the PET Jacobian maps alone, as well as the modulated PET data. The decreased metabolism on the raw FDG maps is not sufficient to survive multiple comparisons correction for whole-brain voxelwise studies. It only becomes apparent with the use of a hippocampal region of interest, which significantly reduces the multiple comparisons problem, allowing statistical significance to be achieved.

An important question is whether there is decreased activity, as a whole, in the hippocampus, taking into consideration the effects of atrophy. The critical piece of information is contained in the degree of expansion and contraction required to match the template. In the case of AD, there is a massive difference in the activity levels in the hippocampus, as manifested on the modulated maps and in the Jacobian maps alone.

**Extrahippocampal Regions**

Some additional, interesting observations arise from an analysis of the modulated and Jacobian maps, with reference to areas outside the hippocampus. On the raw FDG maps, there are large activity differences in the parietal lobes bilaterally, as well as in the cingulate gyrus, which have been demonstrated in numerous FDG-PET studies. With modulation, however, the parietal areas disappear and the cingulate gyrus activity differences become markedly reduced, as well as more restricted to the posterior cingulate. On the Jacobian maps alone, there are no differences identified in either of these regions. In the context of the PET-based normalization procedure, this suggests that these areas have some increased spatial extent of FDG uptake in the patients with AD (or a spatial up-regulation) to compensate for the reduced underlying activity (assuming the difference is not attributable to a regional increase in gray matter volume in the subjects with AD).

**Study-Specific PET Template**

A significant methodologic departure proposed here is the use of a study-specific PET template for the spatial normalization procedure. Many previous studies have used coregistration of PET data to a corresponding MRI in the same subject, and application of the parameters computed from an MRI-to-MRI normalization procedure. The reasoning for this approach is that, due to the inherently higher spatial resolution, the MRI-based normalization is more accurate. This approach assumes that PET activity corresponds to anatomic structure in a consistent manner between disease states and anatomic locations.
This assumption is not biologically plausible, as cerebral metabolic activity levels can vary within anatomic structures, based on metabolic demand and underlying pathology. In addition, this approach universally discards information on local expansion and contraction computed from the MRI-based parameters. The use of a PET-study-specific template allows the valid use of all normalization information (including the Jacobian determinants) to identify population differences based only on FDG-PET data. In previous reports, the use of MRI-to-MRI normalizations would invalidate any unique PET information to be gained from the tissue expansion and contraction coded in the MRI-based transformations. The PET data can contain combinations of information that may be lost when standard MRI-to-MRI normalization is transposed to PET, such as metabolic volumetric differences, activity changes restricted to an anatomic structure, activity differential gradients across an anatomic structure, as well as up-regulation of the spatial extent of activity that may encompass more than a particular anatomic boundary.

The use of modulated data and Jacobian information is more than simply academic in importance. A primary goal of AD research is the search for early biomarkers to diagnose and evaluate treatment effects. Imaging has taken an important role in this regard, with numerous efforts aimed at using both MR imaging and PET imaging data for diagnosis and classification of subjects such as those with AD and MCI, or those who are CN. With regard to PET, much of the sensitivity present in the data for identifying AD in the critical hippocampal regions is not currently being utilized. Incorporation of these additional imaging biomarkers (Jacobian and modulated data) may increase the sensitivity of methods for individual subject diagnosis, including those that rely on univariate statistics, \( z \)-score population comparisons, and the newer machine learning classification approaches.
The differences in analytic approaches are clearly exemplified by comparing power curves and sample sizes required to identify differences in populations for the hippocampal region (Fig 8). Using the modulated PET approach, a difference in populations can be identified using only 12 subjects per group. This is comparable with the power of using MRI VBM alone (8 subjects per group). In contrast, using the conventional PET approach, a 5- to 6-fold increase in subjects (68 subjects per group) is required to observe comparable differences. In addition to the massive loss in sensitivity for identifying subtle differences, this translates to nearly an order of magnitude increase in imaging costs (in this example, well over $100,000, assuming $1000 per PET scan).

Use of Modulated Data
Unlike the case for structural MR imaging analyses, modulated data are typically not used for imaging studies of brain function. For example, in fMRI studies, most investigators are only interested in comparisons of the average signal within each region. Information on the total amount of signal in fMRI (provided by modulated data) within a region is typically not considered. However, total activity may provide a better model for the underlying processes being studied. In this sense, the use of modulated data with functional brain imaging data (fMRI, PET, arterial spin-labeling, etc.) may provide a more appropriate model and better sensitivity, depending on the question being asked.

Reconciling Voxelwise and ROI-Based Studies
We have demonstrated why previous SPM-style voxelwise analyses of AD PET data have not shown strong hippocampal differences. These previous SPM-style analyses are measuring average activity, which is enforced by the spatial normalization process. The average activity within the hippocampi between groups is not greatly different, whereas total activity shows large differences. Activity differences become apparent only with the use of a hippocampal region of interest, which reduces the multiple comparisons problem. ROI methods do not need to correct for multiple comparisons. In this sense, the multiple comparisons correction applied to whole-brain voxelwise studies is potentially the source of differences with ROI-based methods that are also measuring average activity. In addition, some manual and semiautomated ROI-based PET analyses demonstrating hippocampal hypometabolism are probably measuring total activity in the hippocampal region (or mean of total activity between hemispheres). This capability is inherent in the ROI-based approach, regardless of whether each hippocampus is carefully outlined on a corresponding structural image or drawn directly on the PET image itself.

Limitations
There are several potential limitations of our study. For the PET analysis, we used signal-intensity-scaled data from the ADNI data base. There are a variety of signal scaling methods used in PET imaging and continued debate regarding which to use in different circumstances. The ADNI preprocessing is essentially a proportional scaling approach, similar to that of SPM. We performed some analyses using additional proportional scaling in the SPM modeling and had similar results to those reported here. In AD, the cerebellum is probably more normal in FDG activity than the remaining brain; thus, using a cerebellar standard would result in lower supratentorial values for AD and would probably increase the observed cingulate and bilateral parietal activity on the raw FDG maps. It is important to note that a cerebellar normalization procedure can have a profound effect on the reverse AD-CN contrast, in which proportional scaling typically demonstrates large bilateral cerebellar activity differences, which disappear with cerebellar normalization. Thus, some care must be taken in interpreting differences that relate to the regions used for intensity scaling in the frontotemporal dementias. Partial volume effects can result in an underestimation of the metabolic activity. Additional PET analyses performed using a voxelwise gray matter volume regression method to correct for these effects demonstrated similar findings. In many SPM VBM studies, a significant degree of spatial smoothing is used. This has the effect of increasing signal-to-noise for identifying subtle differences, as well as making the data more Gaussian for use with SPM Gaussian random field theory corrections. For this study, smoothing was unnecessary, as we had ample SNR for demonstrating activity differences. In addition, we used stringent Bonferroni corrections for whole-brain analyses, which do not rely on Gaussian random field theory.

Conclusions
We demonstrate the heretofore elusive AD hippocampal FDG-PET activity differences on whole-brain SPM voxelwise analyses to be embedded in spatial normalization Jacobian information. We introduce a PET-specific analysis framework using a PET population template, high-dimensional SyN, and Jacobian information as imaging biomarkers for whole-brain voxelwise FDG-PET analyses. The use of modulated data and Jacobian information may provide novel biomarkers of AD to diagnose and evaluate treatment effects.

Acknowledgments
We thank Benjamin Wagner for computer programming support. Data collection and sharing for this project was funded by ADNI (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott; Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Amorfix Life Sciences; AstraZeneca; Bayer HealthCare; BioClinica; Biogen Idec; Bristol-Myers Squibb; Eisai; Elan Pharmaceuticals; Eli Lilly and Company; F. Hoffmann-La Roche and its affiliated company Genentech; GE Healthcare; Innogenetics; IXICO; Janssen Alzheimer Immunotherapy Research & Development; Johnson & Johnson Pharmaceutical Research & Development; Medpace; Merck & Co.; Meso Scale Diagnostics; Novartis Pharmaceuticals; Pfizer; Servier; Synarc; and Takeda Pharmaceutical. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease
Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by NIH grants P30 AG010129 and K01 AG030514.

References

1. Nestor PJ, Scheltens P, Hodges JR. Advances in the early detection of Alzheimer’s disease. Nat Med 2004;10:534 –41
2. Mevel K, Desgranges B, Baron JC, et al. Detecting hippocampal hypometabolism in mild cognitive impairment using automatic voxel-based approaches. Neuroimage 2007;37:18–25
3. Mosconi L, Tsui WH, De Santi S, et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 2005;64: 1860 –67
4. De Santi S, de Leon MJ, Rusinek H, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001;22: 529–39
5. Ishii K, Sasaki M, Yamaji S, et al. Relatively preserved hippocampal glucose metabolism in mild Alzheimer’s disease. Dement Geriatr Cogn Disord 1998;9: 317–22
6. Kawachi T, Ishii K, Sakamoto S, et al. Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2006;33:801–09
7. de Leon MJ, McRae T, Rusinek H, et al. Cortisol reduces hippocampal glucose metabolism in normal elderly, but not in Alzheimer’s disease. J Clin Endocrinol Metab 1997;82:3251–59
8. Ouchi Y, Nobezawa S, Okada H, et al. Altered glucose metabolism in the hippocampal head in memory impairment. Neurology 1998;51:1336 –42
9. de Leon MJ, Convit A, Wolf OT, et al. Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluorodeoxy-D-glucose/poitreron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 2001;98:10966 –71
10. Nestor PJ, Fryer TD, Smielski P, et al. Limbic hypometabolism in Alzheimer’s disease and mild cognitive impairment. Ann Neurol 2003;54:343–51
11. Matsuda H, Kanetaka H, Ohnishi T, et al. Brain SPET abnormalities in Alzheimer’s disease before and after atrophy correction. Eur J Nucl Med Mol Imaging 2002;29:1502–05
12. Mosconi L, Sorbi S, de Leon MJ, et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer’s disease. J Nucl Med 2006;47: 1778 –86
13. Ashburner J, Friston KJ. Voxel-based morphometry—the methods. Neuroimage 2000;11:805–21
14. Friston KJ, Ashburner J, Poline J, et al. Spatial registration and normalization of images. Hum Brain Mapp 1995;2:165–89
15. Friston KJ, Frith CD, Liddle PF, et al. Comparing functional (PET) images: the assessment of significant change. J Cereb Blood Flow Metab 1991;11:690–99
16. Friston KJ, Passingham RE, Nutt JG, et al. Localisation in PET images: direct fitting of the intercommissural (AC-PC) line. J Cereb Blood Flow Metab 1989; 9:690–95
17. Minoshima S, Frey KA, Koepp RA, et al. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG-PET. J Nucl Med 1995;36:1238–48
18. Mueller SG, Weiner MW, Thal LJ, et al. The Alzheimer’s Disease Neuroimaging Initiative. Neuroimaging Clin N Am 2005;15:869–77, xi-xii
19. Jagust WJ, Bandy D, Chen K, et al. The Alzheimer’s Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement 2010;6: 221–29
20. Landau SM, Harvey D, Madison CM, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 2009; 32:1207–18
21. Avants BB, Epstein CL, Grossman M, et al. Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med Image Anal 2008;12:26–41
22. Klein A, Andersson J, Ardekani BA, et al. Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration. Neuroimage 2009; 46:786 –802
23. Avants B, Gee JC. Geodesic estimation for large deformation anatomical shape averaging and interpolation. Neuroimage 2004;23:S19–50
24. Tosovsky Maroyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcelation of the MNI MRI single-subject brain. Neuroimage 2002;15:273–89
25. Maldjian JA, Laurienti PJ, Kraft RA, et al. An automated method for neuro-anatomical and cytoarchitectonic atlas-based interrogation of MRI data sets. Neuroimage 2003;19:1223–39
26. Hochberg MC, Kasper J, Williamson J, et al. The contribution of osteoarthritis to disability: preliminary data from the Women’s Health and Aging Study. J Rheumatol Suppl 1995;43:16–18
27. Benjamini Y, Drai D, Elmer G, et al. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001;125:279 –84
28. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc 1995;57:289–300
29. Yekutieli D, Hochberg Y. Resampling-based false discovery rate controlling multiple test procedures for correlated test statistics. J Statist Plann Inference 1999;82:171–96
30. Dukart J, Mueller K, Horstmann A, et al. Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies. Neuroimage 2010;49:1490 –95
31. Yakuvev I, Hammers A, Fellgiebel A, et al. SPM-based count normalization provides excellent discrimination of mild Alzheimer’s disease and amnestic mild cognitive impairment from healthy aging. Neuroimage 2009;44:43–50
32. Meltzer CC, Leal JP, Mayberg HS, et al. Correction of PET data for partial volume effects in human cerebral cortex by MR imaging. J Comput Assist Tomogr 1990;14:561–70
33. Müller-Gartner HW, Links JM, Prince JL, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab 1992;12:571–83
34. Casanova R, Srikanth R, Baer A, et al. Biological parametric mapping: A statistical toolbox for multimodality brain image analysis. Neuroimage 2007;34: 137–43